DE3934366A1 - Vakzine zum schutz vor hiv-virusinfektionen, verfahren zu ihrer herstellung und ihre verwendung als diagnostikum und immuntherapeutikum - Google Patents

Vakzine zum schutz vor hiv-virusinfektionen, verfahren zu ihrer herstellung und ihre verwendung als diagnostikum und immuntherapeutikum

Info

Publication number
DE3934366A1
DE3934366A1 DE3934366A DE3934366A DE3934366A1 DE 3934366 A1 DE3934366 A1 DE 3934366A1 DE 3934366 A DE3934366 A DE 3934366A DE 3934366 A DE3934366 A DE 3934366A DE 3934366 A1 DE3934366 A1 DE 3934366A1
Authority
DE
Germany
Prior art keywords
hiv
virus
vaccine
infections
protection against
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
DE3934366A
Other languages
German (de)
English (en)
Other versions
DE3934366C2 (https=
Inventor
Ursula Dr Dietrich
Michalina Dipl Biol Adamski
Hagen Von Dipl Biol Briesen
Herbert Dr Kuehnel
Helga Prof Ruebsamen-Waigmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chemotherapeutisches Forschungsinstitut Georg Speyer Haus
Original Assignee
Chemotherapeutisches Forschungsinstitut Georg Speyer Haus
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=6391493&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE3934366(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chemotherapeutisches Forschungsinstitut Georg Speyer Haus filed Critical Chemotherapeutisches Forschungsinstitut Georg Speyer Haus
Priority to DE3934366A priority Critical patent/DE3934366A1/de
Priority to DK90915992.3T priority patent/DK0495896T3/da
Priority to EP90915992A priority patent/EP0495896B1/de
Priority to DE59006080T priority patent/DE59006080D1/de
Priority to JP51473190A priority patent/JP3152433B2/ja
Priority to AT90915992T priority patent/ATE106748T1/de
Priority to ES90915992T priority patent/ES2055922T3/es
Priority to PCT/EP1990/001729 priority patent/WO1991005567A1/de
Publication of DE3934366A1 publication Critical patent/DE3934366A1/de
Publication of DE3934366C2 publication Critical patent/DE3934366C2/de
Application granted granted Critical
Priority to US08/968,689 priority patent/US5861243A/en
Granted legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/974—Aids related test

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
DE3934366A 1989-10-14 1989-10-14 Vakzine zum schutz vor hiv-virusinfektionen, verfahren zu ihrer herstellung und ihre verwendung als diagnostikum und immuntherapeutikum Granted DE3934366A1 (de)

Priority Applications (9)

Application Number Priority Date Filing Date Title
DE3934366A DE3934366A1 (de) 1989-10-14 1989-10-14 Vakzine zum schutz vor hiv-virusinfektionen, verfahren zu ihrer herstellung und ihre verwendung als diagnostikum und immuntherapeutikum
JP51473190A JP3152433B2 (ja) 1989-10-14 1990-10-12 Ｈｉｖ感染防止用ワクチンおよび免疫療法剤
EP90915992A EP0495896B1 (de) 1989-10-14 1990-10-12 Vakzine zum schutz vor hiv-virusinfektionen, verfahren zu ihrer herstellung und ihre verwendung als diagnostikum und immuntherapeutikum
DE59006080T DE59006080D1 (de) 1989-10-14 1990-10-12 Vakzine zum schutz vor hiv-virusinfektionen, verfahren zu ihrer herstellung und ihre verwendung als diagnostikum und immuntherapeutikum.
DK90915992.3T DK0495896T3 (da) 1989-10-14 1990-10-12 Vaccine til beskyttelse mod HIV-virusinfektioner, fremgangsmåde til fremstilling heraf og anvendelse heraf som diagnostisk middel og immunterapeutisk middel
AT90915992T ATE106748T1 (de) 1989-10-14 1990-10-12 Vakzine zum schutz vor hiv-virusinfektionen, verfahren zu ihrer herstellung und ihre verwendung als diagnostikum und immuntherapeutikum.
ES90915992T ES2055922T3 (es) 1989-10-14 1990-10-12 Vacunas para la proteccion ante infecciones por virus hiv, procedimiento para su preparacion y su uso como agente de diagnostico e inmunoterapeutico.
PCT/EP1990/001729 WO1991005567A1 (de) 1989-10-14 1990-10-12 Vakzine zum schutz vor hiv-virusinfektionen, verfahren zu ihrer herstellung und ihre verwendung als diagnostikum und immuntherapeutikum
US08/968,689 US5861243A (en) 1989-10-14 1997-11-12 Vaccine for protection against HIV infections, process for preparing same and their use as diagnostic and agent immunotherapeutic agent

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE3934366A DE3934366A1 (de) 1989-10-14 1989-10-14 Vakzine zum schutz vor hiv-virusinfektionen, verfahren zu ihrer herstellung und ihre verwendung als diagnostikum und immuntherapeutikum

Publications (2)

Publication Number Publication Date
DE3934366A1 true DE3934366A1 (de) 1991-04-18
DE3934366C2 DE3934366C2 (https=) 1991-11-07

Family

ID=6391493

Family Applications (2)

Application Number Title Priority Date Filing Date
DE3934366A Granted DE3934366A1 (de) 1989-10-14 1989-10-14 Vakzine zum schutz vor hiv-virusinfektionen, verfahren zu ihrer herstellung und ihre verwendung als diagnostikum und immuntherapeutikum
DE59006080T Revoked DE59006080D1 (de) 1989-10-14 1990-10-12 Vakzine zum schutz vor hiv-virusinfektionen, verfahren zu ihrer herstellung und ihre verwendung als diagnostikum und immuntherapeutikum.

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE59006080T Revoked DE59006080D1 (de) 1989-10-14 1990-10-12 Vakzine zum schutz vor hiv-virusinfektionen, verfahren zu ihrer herstellung und ihre verwendung als diagnostikum und immuntherapeutikum.

Country Status (8)

Country Link
US (1) US5861243A (https=)
EP (1) EP0495896B1 (https=)
JP (1) JP3152433B2 (https=)
AT (1) ATE106748T1 (https=)
DE (2) DE3934366A1 (https=)
DK (1) DK0495896T3 (https=)
ES (1) ES2055922T3 (https=)
WO (1) WO1991005567A1 (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0814826A4 (en) * 1995-03-17 2000-01-19 Univ California COMPOSITIONS AND METHODS FOR REDUCING THE ADHESION OF SICK RED BLOOD CELLS
EP0868536A4 (en) * 1995-12-20 2001-11-07 Subsidiary N0 3 Inc GENETIC SUPPRESSOR ELEMENTS AGAINST HIV
EP1849869A3 (fr) * 1994-10-20 2011-05-18 Institut Pasteur Séquences nucléotidiques d'antigènes rétroviraux VIH-1 groupe (ou sous-groupe) 0

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL98845A0 (en) * 1990-07-19 1992-07-15 Merck & Co Inc Coconjugate vaccines comprising immunogenic protein,hiv related peptides,and anionic moieties,their preparation and pharmaceutical compositions containing them
US5274122A (en) * 1992-10-15 1993-12-28 Merck & Co., Inc. Acidic derivatives of homocysteine thiolactone
WO1998041657A1 (en) * 1997-03-20 1998-09-24 Affymetrix, Inc. Iterative resequencing
US5891994A (en) * 1997-07-11 1999-04-06 Thymon L.L.C. Methods and compositions for impairing multiplication of HIV-1
WO2000029561A2 (en) 1999-03-29 2000-05-25 Statens Serum Institut Nucleotide construct with optimised codons for an hiv genetic vaccine based on a primary, early hiv isolate and synthetic envelope
ID30407A (id) 1999-05-13 2001-11-29 American Cyanamid Co Formulasi-formulasi kombinasi bahan penambah
AU784679B2 (en) * 1999-12-23 2006-05-25 International Aids Vaccine Initiative Improvements in or relating to immune responses to HIV
US6399067B1 (en) * 2000-04-28 2002-06-04 Thymon L.L.C. Methods and compositions for impairing multiplication of HIV-1
HUP0600589A2 (en) * 2000-11-10 2006-11-28 Wyeth Corp Adjuvant combination formulations
US8076060B2 (en) * 2003-08-04 2011-12-13 Emil William Chynn Vaccination and immunotherapy as new therapeutic modalities in the treatment of glaucoma
US7563437B2 (en) 2005-02-15 2009-07-21 Thymon, Llc Methods and compositions for impairing multiplication of HIV-1
US20100275278A1 (en) * 2006-02-03 2010-10-28 Karp Nelson M Animal model for hiv induced disease
WO2009155489A2 (en) 2008-06-19 2009-12-23 Variation Biotechnologies, Inc. Compositions and methods for treating influenza
AU2010270722B2 (en) 2009-07-06 2015-06-04 Variation Biotechnologies, Inc. Methods for preparing vesicles and formulations produced therefrom
US9907746B2 (en) 2009-07-06 2018-03-06 Variation Biotechnologies, Inc. Methods for preparing vesicles and formulations produced therefrom
MX342138B (es) 2010-07-06 2016-09-14 Variation Biotechnologies Inc Composiciones y metodos para el tratamiento de influenza.
CA2862864C (en) 2011-01-13 2018-12-11 Variation Biotechnologies Inc. Compositions and methods for treating viral infections
CA2832109C (en) 2011-06-10 2021-07-06 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
US20140356399A1 (en) 2012-01-12 2014-12-04 Variation Biotechnologies, Inc. Compositions and methods for treating viral infections
US20150079077A1 (en) 2012-01-27 2015-03-19 Variation Biotechnologies, Inc. Methods and compositions for therapeutic agents
CN115124628B (zh) * 2021-03-27 2023-03-31 中国科学院昆明植物研究所 一种白及多糖及其制备方法和应用、包含所述白及多糖的免疫佐剂和纳米疫苗

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0347365A2 (en) * 1988-06-14 1989-12-20 QIAGEN GmbH HIV-2 virus variants

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU608294B2 (en) * 1987-01-16 1991-03-28 Institut Pasteur Peptides having immunological properties 2-hiv-2

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0347365A2 (en) * 1988-06-14 1989-12-20 QIAGEN GmbH HIV-2 virus variants

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1849869A3 (fr) * 1994-10-20 2011-05-18 Institut Pasteur Séquences nucléotidiques d'antigènes rétroviraux VIH-1 groupe (ou sous-groupe) 0
EP0814826A4 (en) * 1995-03-17 2000-01-19 Univ California COMPOSITIONS AND METHODS FOR REDUCING THE ADHESION OF SICK RED BLOOD CELLS
US6124262A (en) * 1995-03-17 2000-09-26 The Regents Of The University Of California Compositions and methods for reducing adhesiveness of defective red blood cells
EP0868536A4 (en) * 1995-12-20 2001-11-07 Subsidiary N0 3 Inc GENETIC SUPPRESSOR ELEMENTS AGAINST HIV

Also Published As

Publication number Publication date
JP3152433B2 (ja) 2001-04-03
WO1991005567A1 (de) 1991-05-02
ES2055922T3 (es) 1994-09-01
DE3934366C2 (https=) 1991-11-07
DK0495896T3 (da) 1994-10-10
JPH05505389A (ja) 1993-08-12
DE59006080D1 (de) 1994-07-14
EP0495896B1 (de) 1994-06-08
US5861243A (en) 1999-01-19
ATE106748T1 (de) 1994-06-15
EP0495896A1 (de) 1992-07-29

Similar Documents

Publication Publication Date Title
DE3934366C2 (https=)
DE69527089T2 (de) Monoklonale antikörper gegen hiv-1 und davon hergestellte impfstoffe
DE3855947T2 (de) Peptide mit den immunologischen Eigenschaften von HIV-2
EP0591914B1 (de) Retrovirus aus der HIV-Gruppe und dessen Verwendung
DE3588251T2 (de) DNS-Fragmente des GAG-Gens von LAV
DE69222303T2 (de) Kationisierte antikörper gegen intrazelluläre eiweisse
DE69535147T3 (de) Überexpression von säugetier- und virusproteinen
DE60110822T2 (de) Zubereitung zur immunisierung gegen den aids-virus
DE69129034T3 (de) Molekulare klone von hiv-1 und deren verwendung
DE68926499T2 (de) Synthetisches antigen zum bewirken einer anti-hiv-reaktion
DE3650032T2 (de) Anticytomegaloviraler menschlicher monoklonaler antikörper und dessen herstellung.
DE69028951T2 (de) Oligonukleotiden-Sequenzen zur Amplifizierung von HIV-2 und SIV Retrovirusgenomen, ihre Verwendung zur In-vitro-Diagnostik von durch diese Viren verursachten Infektionen
DE69610295T2 (de) Von einem retroviralen regulationsprotein abstammende, detoxifierte immunogene, dagegen gerichtete antikörper, verfahren zur deren herstellung und diese immunogene oder antikörper enthaltende, pharmazeutische zusammensetzungen.
DE4006630A1 (de) Humane monoklonale antikoerper gegen tollwutviren, ihre herstellung und verwendung
EP1200126A1 (de) Verwendung cd28 spezifischer monoklonaler antikörper zur herstellung einer pharmazeutischen zusammensetzung zur behandlung von virusinfektionen
DE69434961T2 (de) Funktion und aktivität des viralen proteins r (vpr)
DE69830325T2 (de) Peptide, die vom Gen env des FIV (Virus der felinen Immuneffizienz) abgeleitet sind sowie auf ihre immunprotektiven Anwendungen
DE69213325T2 (de) Gegen das menschliche Immunschwäche-Virus gerichtetes Immunpräparat
EP0658119B1 (de) Neue hiv-1-virusisolate eines subtyps und seine differentielle diagnostik, vakzine gegen hiv-1-virusinfektionen dieses subtyps und verfahren zu ihrer herstellung, verwendung der hiv-1-virusisolate
DE69615685T2 (de) Impstoff gegen krankheitserreger, zusammensetzung zur behandlung und vorbeugung von hiv infektionen
CH664575A5 (de) Verfahren zur herstellung eines interferonpraeparates mit antiviraler aktivitaet.
DE68926813T2 (de) Von gemeinsamen sequenzen von antigenen und antiidiotypischen antikörpern oder von antikörpern mit spezifizität für die zellulären rezeptoren der antigene abgeleitete immunogene und biologisch aktive peptide
DE60034243T2 (de) Rekombinante bifunktionale fusionsproteine zur abtreibung variabler viren
WO1998019160A2 (de) VERFAHREN ZUR INDIREKTEN BESTIMMUNG DER TYP I INTERFERON-PRODUKTION IN VIVO MITTELS ANTIKÖRPER GEGEN HUMANE Mx-PROTEINE SOWIE ANTIKÖRPER HIERZU
DE69112392T2 (de) Bcrf1-antagonisten zur behandlung von epstein-barr-virus-infektionen.

Legal Events

Date Code Title Description
OP8 Request for examination as to paragraph 44 patent law
D2 Grant after examination
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee